Shukra Pharmaceuticals Ltd vs Divis Laboratories Ltd
A side-by-side comparison of Shukra Pharmaceuticals Ltd (524632) and Divis Laboratories Ltd (DIVISLAB) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Divis Laboratories Ltd leads 524632 vs DIVISLAB on 8 of 14 metrics (1 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
Valuation
How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
How efficiently each company turns capital and sales into profit. Higher is better.
Growth
Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free.", "Company is expected to give good quarter", "Company has delivered good profit growth of 175% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 28.2%"]
- − ["Stock is trading at 15.5 times its book value", "Debtor days have increased from 122 to 148 days."]
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
- − ["Stock is trading at 12.8 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.